Europe to boost cooperation with international partners on generics

Posted on Updated on

07/08/2014

Europe to boost cooperation with international partners on generics

European system to be used as model to facilitate assessment of medicines

The European Union’s decentralised procedure is being used as a model to accelerate the assessment of applications for generic medicines as part of theInternational Generic Drug Regulators PilotExternal link icon (IGDRP).

The European Union (EU) is leading an international pilot project through which, upon request from a generic pharmaceutical company, it will share the assessment reports generated as part of the decentralised procedure in real time with collaborating regulatory agencies outside the EU.

By offering to share its assessment reports, the EU aims to reinforce collaboration and information-sharing between regulatory authorities across the world, contributing to facilitating and strengthening the scientific assessment process for medicines. This should enable medicines to be authorised in different territories in a coordinated way at approximately the same time.

The first phase of the pilot project will involve the EU, Australia, Canada, Chinese Taipei and Switzerland.

 

 

Other members of the IGDRP may decide to take part in the pilot programme at a later stage. These include Brazil, China, Japan, Korea, Mexico, New Zealand, Russia, Singapore and South Africa. The European Directorate for the Quality of Medicines & HealthcareExternal link icon (EDQM) and the World Health OrganizationExternal link icon (WHO) participate as observers.

Further information about how to participate in the pilot programmeExternal link icon can be found on the website of the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh).

This initiative is one of the work packages of the IGDRP. Other areas of cooperation in which the EU is involved include work sharing possibilities in the area of active substance master file, inspection of sites conducting bioequivalence and bio-analytical studies and information sharing on pharmaceutical quality issues.

The IGDRP was launched in April 2012 to promote collaboration and convergence in generic medicines regulatory programmes in order to address the challenges posed by increasing workloads, globalisation and complexity of scientific issues.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s